Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 283

Related Citations for PubMed (Select 20660600)

1.

A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Rajeshkumar NV, Rasheed ZA, García-García E, López-Ríos F, Fujiwara K, Matsui WH, Hidalgo M.

Mol Cancer Ther. 2010 Sep;9(9):2582-92. doi: 10.1158/1535-7163.MCT-10-0370. Epub 2010 Jul 26.

2.

Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.

Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.

Cancer Lett. 2013 Jul 10;335(1):41-51. doi: 10.1016/j.canlet.2013.01.054. Epub 2013 Feb 10.

3.

Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.

DeRosier LC, Huang ZQ, Sellers JC, Buchsbaum DJ, Vickers SM.

J Gastrointest Surg. 2006 Nov;10(9):1291-300; discussion 1300.

PMID:
17114015
4.

Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.

Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK.

Cancer Res. 2007 Oct 15;67(20):9903-12.

5.

Autophagy mediates survival of pancreatic tumour-initiating cells in a hypoxic microenvironment.

Rausch V, Liu L, Apel A, Rettig T, Gladkich J, Labsch S, Kallifatidis G, Kaczorowski A, Groth A, Gross W, Gebhard MM, Schemmer P, Werner J, Salnikov AV, Zentgraf H, Büchler MW, Herr I.

J Pathol. 2012 Jul;227(3):325-35. doi: 10.1002/path.3994. Epub 2012 Apr 18.

PMID:
22262369
6.

Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract.

Ottinger S, Klöppel A, Rausch V, Liu L, Kallifatidis G, Gross W, Gebhard MM, Brümmer F, Herr I.

Int J Cancer. 2012 Apr 1;130(7):1671-81. doi: 10.1002/ijc.26168. Epub 2011 Jul 21.

PMID:
21544815
7.

Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.

Zhang GN, Liang Y, Zhou LJ, Chen SP, Chen G, Zhang TP, Kang T, Zhao YP.

Cancer Lett. 2011 Dec 27;313(2):137-44. doi: 10.1016/j.canlet.2011.05.030. Epub 2011 Jun 24.

PMID:
22030254
8.

A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.

Kawanami T, Takiguchi S, Ikeda N, Funakoshi A.

Oncol Rep. 2012 Mar;27(3):867-72. doi: 10.3892/or.2011.1597. Epub 2011 Dec 20.

PMID:
22200743
9.

Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.

Hu G, Li F, Ouyang K, Xie F, Tang X, Wang K, Han S, Jiang Z, Zhu M, Wen D, Qin X, Zhang L.

Int J Oncol. 2012 Mar;40(3):798-806. doi: 10.3892/ijo.2011.1254. Epub 2011 Nov 7.

PMID:
22076649
10.

Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.

Fujisawa T, Nakashima H, Nakajima A, Joshi BH, Puri RK.

Int J Cancer. 2011 Mar 1;128(5):1221-31. doi: 10.1002/ijc.25437.

PMID:
20473925
11.

Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.

Mueller MT, Hermann PC, Witthauer J, Rubio-Viqueira B, Leicht SF, Huber S, Ellwart JW, Mustafa M, Bartenstein P, D'Haese JG, Schoenberg MH, Berger F, Jauch KW, Hidalgo M, Heeschen C.

Gastroenterology. 2009 Sep;137(3):1102-13. doi: 10.1053/j.gastro.2009.05.053. Epub 2009 Jun 6.

PMID:
19501590
12.

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.

Hage C, Rausch V, Giese N, Giese T, Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Herr I.

Cell Death Dis. 2013 May 9;4:e627. doi: 10.1038/cddis.2013.158.

13.

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5.

Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A.

Cell Death Differ. 2008 Apr;15(4):751-61. doi: 10.1038/sj.cdd.4402306. Epub 2008 Jan 25.

14.

Anti-tumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model.

Straughn JM Jr, Oliver PG, Zhou T, Wang W, Alvarez RD, Grizzle WE, Buchsbaum DJ.

Gynecol Oncol. 2006 Apr;101(1):46-54. Epub 2005 Nov 4.

PMID:
16271751
15.

BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.

Awasthi N, Zhang C, Ruan W, Schwarz MA, Schwarz RE.

Mol Cancer Ther. 2012 Dec;11(12):2644-53. doi: 10.1158/1535-7163.MCT-12-0447. Epub 2012 Oct 9.

16.

Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.

Awasthi N, Schwarz MA, Schwarz RE.

Cancer Biol Ther. 2010 Jul 1;10(1):99-107. Epub 2010 Jul 26.

17.

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.

Forero-Torres A, Infante JR, Waterhouse D, Wong L, Vickers S, Arrowsmith E, He AR, Hart L, Trent D, Wade J, Jin X, Wang Q, Austin T, Rosen M, Beckman R, von Roemeling R, Greenberg J, Saleh M.

Cancer Med. 2013 Dec;2(6):925-32. doi: 10.1002/cam4.137. Epub 2013 Oct 25.

18.

TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.

Derosier LC, Vickers SM, Zinn KR, Huang Z, Wang W, Grizzle WE, Sellers J, Stockard CR Jr, Zhou T, Oliver PG, Arnoletti P, Lobuglio AF, Buchsbaum DJ.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3198-207.

19.

Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.

Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T, Yamashita Y, Yamada N, Ohira M, Hirakawa K.

Clin Cancer Res. 2006 Aug 15;12(16):4925-32.

20.

Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.

Buchsbaum DJ, Zhou T, Grizzle WE, Oliver PG, Hammond CJ, Zhang S, Carpenter M, LoBuglio AF.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3731-41.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk